Genmab A (GMAB) stock forecast and price target
Price $51.37 · data as of November 13, 2026
12-month price target
Gold marker: average target · white marker: today’s price ($51.37)
Analyst ratings
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $1.26 | — | $30.0B |
| Next fiscal year ends December 31, 2027 | $1.73 | — | $36.3B |
| Next quarter ends December 31, 2026 | $0.20 | — | $8.4B |
| Quarter after ends March 31, 2027 | $0.30 | — | $7.2B |
Consensus of the analysts covering Genmab A, updated daily. In the last 30 days 3 estimates were raised and 1 lowered.
Our model vs. Wall Street
Analysts see 26.6% upside over 12 months. Our discounted cash flow model with moderate assumptions puts Genmab A’s intrinsic value about 35% above today’s market value, and it scores 2.0 out of 5 on our checks. Price targets follow sentiment; a DCF follows cash. When both point the same way the signal is stronger. Try your own assumptions.
Frequently asked questions
What is the Genmab A stock price target?
The average 12-month target from 11 analysts is $65.01, 26.6% above the current price of $51.37 Targets range from $48.00 to $80.00.
Is Genmab A a buy according to analysts?
The consensus rating is “Strong buy” (1 strong buy, 9 buy, 2 hold). Ratings are opinions, not guarantees; this is not investment advice.
How much is Genmab A expected to earn?
Analysts expect EPS of $1.26 for the fiscal year ending December 31, 2026 and $1.73 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.